Literature DB >> 21704537

Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry.

Bo Yang1, Hang Sun, Wei Lin, Wugang Hou, Hang Li, Liying Zhang, Fanfan Li, Yu Gu, Yue Song, Qing Li, Feng Zhang.   

Abstract

OBJECTIVE: To identify the differences of 5-methylcytosine (5-MC) level between primary prostate cancer tissues (PCTs), prostate cancer-adjacent benign tissues (PCABTs), low-grade prostatic intraepithelial neoplasia (LGPIN), and high-grade prostatic intraepithelial neoplasia (HGPIN), and further analysis the 5-MC alterations in prostate cancer with pathologic grade and clinical prognosis.
MATERIALS AND METHODS: Immunohistochemistry method with a 5-MC monoclonal antibody was used to identify the 5-methylcytosine (5-MC) levels in PCTs, PCABTs, LGPIN, and HGPIN specimens in the present study. Statistical analysis with SPSS software (SPSS Inc., Chicago, IL) was used to compare differences of 5-MC levels in the four groups and evaluate the 5-MC alterations in prostate cancer with pathologic grade and clinical prognosis.
RESULTS: We found that 38 of 48 (79.1%) patients studied showed a decrease in 5-MC staining of PCTs compared with PCABTs. The difference in the methylation levels for the PCTs and the PCABTs was highly statistically significant (P < 0.001). Spearman correlation showed there was no statistically significant association between the average score of 5-MC staining and Gleason score sum. Kaplan-Meier survival analysis showed that patient group with no or weak 5-MC staining compared with group with moderate and strong 5-MC staining was associated with better survival of patients, although there was no statistically significant difference between the 2 groups in predicating prognosis (P = 0.385). The average scores of 5-MC staining for LGPIN, HGPIN, PCABTs, and PCTs groups were 6.91, 1.58, 6.63, and 3.10, respectively. The methylation level of HGPIN group, as well as that of PCTs group, was significantly lower than those of LGPIN (P < 0.001; P < 0.001) and PCABTs groups (P < 0.001; P < 0.001), respectively, with the 5-MC levels of PCABTS group similar to that of LGPIN group (P = 0.476). 5-MC levels of HGPIN group was lower than that PCTs group (P = 0.004).
CONCLUSIONS: We found that global DNA methylation was low in most prostate cancer compared with benign regions from the same patient's sections. None of the DNA hypomethylation changes in primary cancers were associated with pathologic grade and clinical prognosis. In addition, immunohistochemistry showed that the global methylation was lower in HGPIN compared with LGPIN and methylcytosine staining in HGPIN was lower than that of PCTs. The results suggest that global DNA hypomethylation might play an important role in the process of prostate cancer initiation rather than progression.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704537     DOI: 10.1016/j.urolonc.2011.05.009

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  14 in total

Review 1.  Epigenetic susceptibility factors for prostate cancer with aging.

Authors:  N A Damaschke; B Yang; S Bhusari; J P Svaren; D F Jarrard
Journal:  Prostate       Date:  2013-09-02       Impact factor: 4.104

Review 2.  Global DNA hypomethylation in prostate cancer development and progression: a systematic review.

Authors:  R Zelic; V Fiano; C Grasso; D Zugna; A Pettersson; A Gillio-Tos; F Merletti; L Richiardi
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-11-11       Impact factor: 5.554

Review 3.  Epigenetic linkage of aging, cancer and nutrition.

Authors:  Michael Daniel; Trygve O Tollefsbol
Journal:  J Exp Biol       Date:  2015-01-01       Impact factor: 3.312

Review 4.  Dietary factors and epigenetic regulation for prostate cancer prevention.

Authors:  Emily Ho; Laura M Beaver; David E Williams; Roderick H Dashwood
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

Review 5.  Epigenetic effects of green tea polyphenols in cancer.

Authors:  Susanne M Henning; Piwen Wang; Catherine L Carpenter; David Heber
Journal:  Epigenomics       Date:  2013-12       Impact factor: 4.778

6.  Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer.

Authors:  Bing Yang; Sachin Bhusari; Jessica Kueck; Pushpa Weeratunga; Jennifer Wagner; Glen Leverson; Wei Huang; David F Jarrard
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

7.  Clinicopathological significance and prognostic value of DNA methyltransferase 1, 3a, and 3b expressions in sporadic epithelial ovarian cancer.

Authors:  Xuefeng Bai; Zhiguo Song; Yingzi Fu; Zhaojin Yu; Lin Zhao; Haishan Zhao; Weifan Yao; Desheng Huang; Xiaoyi Mi; Enhua Wang; Zhihong Zheng; Minjie Wei
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

8.  Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile.

Authors:  Luciane Tsukamoto Kagohara; Juliana L Schussel; Tejaswini Subbannayya; Nandini Sahasrabuddhe; Cynthia Lebron; Mariana Brait; Leonel Maldonado; Blanca L Valle; Francesca Pirini; Martha Jahuira; Jaime Lopez; Pablo Letelier; Priscilla Brebi-Mieville; Carmen Ili; Akhilesh Pandey; Aditi Chatterjee; David Sidransky; Rafael Guerrero-Preston
Journal:  Future Oncol       Date:  2014-07-28       Impact factor: 3.404

9.  Reduced 5-methylcytosine level as a potential progression predictor in patients with T1 or non-invasive urothelial carcinoma.

Authors:  Chi-Jung Chung; Chao-Hsiang Chang; Chih-Pin Chuu; Chi-Rei Yang; Yi-Huei Chang; Chi-Ping Huang; Wen-Chi Chen; Mu-Chi Chung; Han Chang
Journal:  Int J Mol Sci       Date:  2014-12-30       Impact factor: 5.923

10.  Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.

Authors:  Giorgia Gurioli; Samanta Salvi; Filippo Martignano; Flavia Foca; Roberta Gunelli; Matteo Costantini; Giacomo Cicchetti; Ugo De Giorgi; Persio Dello Sbarba; Daniele Calistri; Valentina Casadio
Journal:  J Transl Med       Date:  2016-08-30       Impact factor: 8.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.